ZUMA-7 — Axicabtagene Ciloleucel Versus Standard Care as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)

Phase 3 · 2022 · Diffuse Large B-Cell Lymphoma

Design

Randomized trial of axicabtagene ciloleucel versus standard second-line care (salvage chemoimmunotherapy followed by autologous stem-cell transplant in responders).

Population

Large B-cell lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy.

Primary Endpoint

event-free survival (EFS)

Key Result

EFS 8.3 vs 2.0 months (HR 0.40) and a final overall-survival benefit (HR 0.73) versus standard care.

Guideline Impact

NCCN category 1 axicabtagene ciloleucel for primary refractory or early-relapsing large B-cell lymphoma